Have one of the following solid tumor cancers: * Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer * Cohort A2/B1/B2: urothelial carcinoma * Cohort C: triple negative breast cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, HNSCC (head and neck squamous cell carcinoma), esophageal cancer, pancreatic cancer, or prostate cancer

Prior Systemic Therapy Criteria: * Cohort A1/C: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies * Cohort A2/B1/B2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies.

Prior enfortumab vedotin specific requirements: * Cohorts A1/A2/C: prior treatment with enfortumab vedotin is allowed, but not required * Cohort B1: individual must be enfortumab vedotin naive in the advanced/metastatic setting * Cohort B2: individual must have received enfortumab vedotin in the metastatic/advanced setting.

Measurability of disease * Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1) * Cohorts A2, B1, B2, C: measurable disease required as defined by RECIST v1.1

Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country specific regulations

Minimum age: 18

Individual with known or suspected uncontrolled CNS metastases

Individual with uncontrolled hypercalcemia

Individual with uncontrolled diabetes

Individual with evidence of corneal keratopathy or keratitis, and history of corneal transplant

Any serious unresolved toxicities from prior therapy

Significant cardiovascular disease

Recent thromboembolic event or bleeding disorder

Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms

History of pneumonitis/interstitial lung disease

History of Grade ≥3 skin toxicity when receiving enfortumab vedotin

Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention